Sturlimogene Erparepvec
Sarcomatoid Renal Cell Carcinoma
Explore 10 assets in Sarcomatoid Renal Cell Carcinoma →Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
City of Hope Medical Center
Modality
UNKNOWN
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07218692CT.gov RP2 and Tivozanib for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy | — | Not Yet Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Sarcomatoid Renal Cell Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Sturlimogene Erparepvec (this asset) | City of Hope Medical Center | P2 | CCC · 53 |
| Nivolumab | City of Hope Medical Center | P3 | BB |
| Sorafenib | National Cancer Institute (NCI) | P2 | BB |
| Ipilimumab | City of Hope Medical Center | P3 | BB |
| Cabozantinib | City of Hope Medical Center | P3 | BB |
| Pazopanib | Mayo Clinic | P2 | B |
| Clostridium Butyricum Miyairi 588 | City of Hope Medical Center | P2 | B |
| Adriamycin | Eastern Cooperative Oncology Group | P2 | B |
| Trebananib | National Cancer Institute (NCI) | P2 | B |
+8 more in the Sarcomatoid Renal Cell Carcinoma cohort
Other indications for Sturlimogene Erparepvec
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Nonpapillary Renal Cell Carcinoma | — | P2 | CCC · 53 |
| Renal Cell Carcinoma | — | P2 | CCC · 53 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Sturlimogene Erparepvec in Sarcomatoid Renal Cell Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/sturlimogene-erparepvec-sarcomatoid-renal-cell-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →